Formulary Search
Search Results : Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs (Atomoxetine hydrochloride - Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs)
Show Icon and Status Keys
- Capsules
- Oral solution
Stable patients (cohort 1) = BLUE (with specialist team initiation) where:
- open-access discharge has been accepted by GP practice under the LCS from SABPFT.
- and the treatment is stabilised, prior to transfer of care.
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 1), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
- Oral solution
Patients currently receiving specialist treatment for other mental health or neurological comorbidities (cohort 2) = AMBER (shared care)
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 2), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
- Oral solution
Complex patients (cohort 3) = Red (will remain with the specialist service)
- Oral solution
- Tablets
Stable patients (cohort 1) = BLUE (with specialist team initiation) where:
- open-access discharge has been accepted by GP practice under the LCS from SABPFT.
- and the treatment is stabilised, prior to transfer of care.
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 1), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Oral solution
- Tablets
Patients currently receiving specialist treatment for other mental health or neurological comorbidities (cohort 2) = AMBER (shared care)
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 2), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Oral solution
- Tablets
Complex patients (cohort 3) = Red (will remain with the specialist service)
- Modified release tablets
Stable patients (cohort 1) = BLUE (with specialist team initiation) where:
- open-access discharge has been accepted by GP practice under the LCS from SABPFT.
- and the treatment is stabilised, prior to transfer of care.
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 1), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Modified release tablets
Patients currently receiving specialist treatment for other mental health or neurological comorbidities (cohort 2) = AMBER (shared care)
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 2), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Modified release tablets
Complex patients (cohort 3) = Red (will remain with the specialist service)
- Capsules
Stable patients (cohort 1) = BLUE (with specialist team initiation) where:
- open-access discharge has been accepted by GP practice under the LCS from SABPFT.
- and the treatment is stabilised, prior to transfer of care.
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 1), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
Patients currently receiving specialist treatment for other mental health or neurological comorbidities (cohort 2) = AMBER (shared care)
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 2), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
Complex patients (cohort 3) = Red (will remain with the specialist service)
- Modified release capsules
- Modified release tablets
- Oral solution
- Tablets
Modified-release: Prescribe by brand. Xaggitin XL and Affenid XL are the locally agreed brands with stock availability.
Stable patients (cohort 1) = BLUE (with specialist team initiation) where:
- open-access discharge has been accepted by GP practice under the LCS from SABPFT.
- and the treatment is stabilised, prior to transfer of care.
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 1), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Modified release capsules
- Modified release tablets
- Oral solution
- Tablets
Modified-release: Prescribe by brand. Xaggitin XL and Affenid XL are the locally agreed brands with stock availability.
Patients currently receiving specialist treatment for other mental health or neurological comorbidities (cohort 2) = AMBER (shared care)
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 2), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Modified release capsules
- Modified release tablets
- Oral solution
- Tablets
Modified-release: Prescribe by brand. Xaggitin XL and Affenid XL are the locally agreed brands with stock availability.
Complex patients (cohort 3) = Red (will remain with the specialist service)